Evidence map›Paper›PMID 28278723›Full record

Trial reportLeukemia & lymphoma2017

Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.

Abhishek Maiti, Jorge Cortes, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Susan O'Brien, Hagop Kantarjian

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abhishek Maitia Department of Internal Medicine , The University of Texas Health Sciences Center at Houston , TX , USA.
Jorge Cortesb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Alessandra Ferrajolib Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Zeev Estrovb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Gautam Borthakurb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Guillermo Garcia-Manerob Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Elias Jabbourb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Farhad Ravandib Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Susan O'Brienc Chao Family Comprehensive Cancer Center, University of California , Irvine , CA , USA.
Hagop Kantarjianb Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 1990 to 2014
$41.8M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlast CrisisFemaleHarringtoninesHomoharringtonineHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Accelerated PhaseLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedNeoplasm StagingRetreatmentHarringtoninesHomoharringtonineImatinib Mesylate

Identifiers

PMID28278723
PMCPMC5478443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.